Clinical Trial: Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignancies

U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT07493174) titled 'Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignancies' on March 19.

Brief Summary: (Limit: 5000 characters) The purpose of this phase I clinical study aims to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SYS6055 Injection in participants with relapsed/refractory B-cell malignancies, and to provide evidence for recommending a dosage regimen for subsequent studies.

Study Start Date: April 15

Study Type: INTERVENTIONAL

Condition: Relapsed/Refractory B-Cell Malignancies

Intervention: DRUG: SYS6055

The dose will be select...